{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:39:35Z","timestamp":1761597575949},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003179","name":"Alberta Heritage Foundation for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-130273","MFE-135542","AI046464","AI082263"],"award-info":[{"award-number":["MOP-130273","MFE-135542","AI046464","AI082263"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["C06 RR016226"],"award-info":[{"award-number":["C06 RR016226"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.vaccine.2015.01.057","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T15:19:06Z","timestamp":1423063146000},"page":"1317-1323","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice"],"prefix":"10.1016","volume":"33","author":[{"given":"Rolando","family":"Pajon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn M.","family":"Buckwalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay O.","family":"Johswich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Gray-Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.01.057_bib0250","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0255","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1365-3156.2007.01929.x","article-title":"Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci","volume":"12","author":"Dellicour","year":"2007","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0265","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","article-title":"Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks","volume":"25","author":"Taha","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0270","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0275","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0280","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0285","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0290","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0295","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0300","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/j.vaccine.2011.04.095","article-title":"Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys","volume":"29","author":"Koeberling","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0305","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1473-3099(13)70341-4","article-title":"A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0310","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0315","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0320","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0325","doi-asserted-by":"crossref","first-page":"e1003509","DOI":"10.1371\/journal.ppat.1003509","article-title":"In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa","volume":"9","author":"Johswich","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0330","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CVI.00403-08","article-title":"Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","volume":"16","author":"Koeberling","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0335","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0340","doi-asserted-by":"crossref","first-page":"e1002688","DOI":"10.1371\/journal.ppat.1002688","article-title":"The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein","volume":"8","author":"Beernink","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0345","doi-asserted-by":"crossref","first-page":"e66536","DOI":"10.1371\/journal.pone.0066536","article-title":"Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa","volume":"8","author":"Pajon","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0350","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.1003470","article-title":"A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination","volume":"186","author":"Beernink","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0355","doi-asserted-by":"crossref","first-page":"e10067","DOI":"10.1371\/journal.pone.0010067","article-title":"Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils","volume":"5","author":"Gu","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0360","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/IAI.05182-11","article-title":"Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding","volume":"79","author":"Giuntini","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0365","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01625-14","article-title":"Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding","volume":"5","author":"Costa","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0370","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0375","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0380","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0140-6736(92)92411-8","article-title":"Herd immunity and the meningococcal vaccine trial in Norway","volume":"340","author":"Bjune","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0385","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1016\/j.vaccine.2013.06.080","article-title":"Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage","volume":"31","author":"Delbos","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0390","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0395","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0140-6736(14)60935-1","article-title":"Meningococcal carriage: the dilemma of 4CMenB vaccine","volume":"384","author":"Taha","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0400","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1016\/j.vaccine.2011.07.124","article-title":"An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups","volume":"29","author":"Pinto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0405","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2010.08.048","article-title":"A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA","volume":"28","author":"Keiser","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0410","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/IAI.01108-08","article-title":"Genetically modified L3, 7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response","volume":"77","author":"Weynants","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0415","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.vaccine.2014.03.068","article-title":"A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA)","volume":"32","author":"Koeberling","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0420","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0425","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/CVI.00542-10","article-title":"A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines","volume":"18","author":"Koeberling","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0430","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/infdis\/jir466","article-title":"Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation","volume":"204","author":"Ibarz-Pavon","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0440","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0445","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0450","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/521833","article-title":"Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial","volume":"196","author":"O\u2019Brien","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0455","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jama.1993.03500020080036","article-title":"Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination","volume":"269","author":"Murphy","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0460","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3476(05)83529-2","article-title":"Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine","volume":"122","author":"Murphy","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0465","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00006454-199306000-00005","article-title":"Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine","volume":"12","author":"Barbour","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0470","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/IAI.00141-08","article-title":"Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells","volume":"76","author":"Trzcinski","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0475","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1348-0421.2011.00352.x","article-title":"Th17 cells contribute to nontypeable Haemophilus influenzae-specific protective immunity induced by nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide","volume":"55","author":"Noda","year":"2011","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0480","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/mi.2009.139","article-title":"Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection","volume":"3","author":"Feinen","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0485","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mi.2012.12","article-title":"Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-beta-dependent mechanisms","volume":"5","author":"Liu","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2015.01.057_bib0490","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1073\/pnas.1314688110","article-title":"Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model","volume":"111","author":"Warfel","year":"2014","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15001140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15001140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T14:44:13Z","timestamp":1651157053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15001140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0264410X15001140"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}